263 related articles for article (PubMed ID: 23957759)
1. A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis.
Hadjigeorgiou GM; Doxani C; Miligkos M; Ziakas P; Bakalos G; Papadimitriou D; Mprotsis T; Grigoriadis N; Zintzaras E
J Clin Pharm Ther; 2013 Dec; 38(6):433-9. PubMed ID: 23957759
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
[TBL] [Abstract][Full Text] [Related]
3. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
[TBL] [Abstract][Full Text] [Related]
4. Natalizumab for relapsing remitting multiple sclerosis.
Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
[TBL] [Abstract][Full Text] [Related]
5. Network analysis of randomized controlled trials in multiple sclerosis.
Zintzaras E; Doxani C; Mprotsis T; Schmid CH; Hadjigeorgiou GM
Clin Ther; 2012 Apr; 34(4):857-869.e9. PubMed ID: 22444787
[TBL] [Abstract][Full Text] [Related]
6. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
7. Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
Roskell NS; Zimovetz EA; Rycroft CE; Eckert BJ; Tyas DA
Curr Med Res Opin; 2012 May; 28(5):767-80. PubMed ID: 22462530
[TBL] [Abstract][Full Text] [Related]
8. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
Nikfar S; Rahimi R; Abdollahi M
Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review.
Galetta SL; Markowitz C; Lee AG
Arch Intern Med; 2002 Oct; 162(19):2161-9. PubMed ID: 12390057
[TBL] [Abstract][Full Text] [Related]
10. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
Hutchinson M; Fox RJ; Havrdova E; Kurukulasuriya NC; Sarda SP; Agarwal S; Siddiqui MK; Taneja A; Deniz B
Curr Med Res Opin; 2014 Apr; 30(4):613-27. PubMed ID: 24195574
[TBL] [Abstract][Full Text] [Related]
12. Considerations in the treatment of relapsing-remitting multiple sclerosis.
Calabresi PA
Neurology; 2002 Apr; 58(8 Suppl 4):S10-22. PubMed ID: 11971122
[TBL] [Abstract][Full Text] [Related]
13. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis.
McCool R; Wilson K; Arber M; Fleetwood K; Toupin S; Thom H; Bennett I; Edwards S
Mult Scler Relat Disord; 2019 Apr; 29():55-61. PubMed ID: 30677733
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1016-20. PubMed ID: 25550414
[TBL] [Abstract][Full Text] [Related]
15. Comparative studies of glatiramer acetate and interferon beta.
Goodin D
Int MS J; 2008 Jun; 15(2):39-41. PubMed ID: 18782497
[TBL] [Abstract][Full Text] [Related]
16. [Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].
; Rieckmann P
Nervenarzt; 2006 Dec; 77(12):1506-18. PubMed ID: 17136556
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on subcutaneous recombinant interferon-beta-1a (Rebif) in relapsing-remitting multiple sclerosis.
Murdoch D; Lyseng-Williamson KA
BioDrugs; 2005; 19(5):323-5. PubMed ID: 16207073
[TBL] [Abstract][Full Text] [Related]
18. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
[TBL] [Abstract][Full Text] [Related]
19. Glatiramer acetate for multiple sclerosis.
La Mantia L; Munari LM; Lovati R
Cochrane Database Syst Rev; 2010 May; (5):CD004678. PubMed ID: 20464733
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
